SEC Form 4 · accession 0001628280-26-041575
Prime Medicine, Inc. · PRME
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey D Marrazzo
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 8, 2026 · 4:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001894562
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.06 | Jun 5, 2026 | A | 75,000 | A | — | Jun 5, 2036 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.